Hazard Information | Back Directory | [Uses]
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL)[1]. | [in vivo]
Veltuzumab (i.v. or s.c.; 5, 20 and 60 μg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses[1].
Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo[1]. Animal Model: | Lymphoma xenograft model[1] | Dosage: | 5, 20 and 60 μg | Administration: | intraperitoneal and subcutaneous, single | Result: | Showed low dose of 0.05 μg increased the MST. |
Animal Model: | SCID mice[1] | Dosage: | 0.5, 0.25, 0.1, or 0.05 μg; 35, 3.5, 0.35, or 0.035 μg | Administration: | intraperitoneal, single | Result: | Improved significantly survival. |
| [References]
[1] David M Goldenberg, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood DOI:10.1182/blood-2008-07-168146 |
|
Company Name: |
NCE Biomedical Co.,Ltd.
|
Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
Website: |
www.approvedhomemanagement.com/ShowSupplierProductsList15748/0.htm |
Company Name: |
SPIRO PHARMA
|
Tel: |
|
Website: |
www.spiropharma.com.cn |
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
|